July 15, 2025

Table 2 from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer

View Full Paper

Ask AI

Bookmark

MAIN FINDING: The study evaluates the safety of the CDK2/4/6 inhibitor PF-06873600 in combination with endocrine therapy.
KEY EVIDENCE: Over 15% of patients experienced treatment-emergent adverse events (TEAEs), with safety data collected from 151 participants.
APPROACH: The trial followed a Phase I/IIa design to assess the effects on patients with breast cancer receiving the treatment.
SIGNIFICANCE: Results suggest potential benefits and risks of combining CDK inhibitors with endocrine therapy for breast cancer treatment.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Phase I/IIa trial assessed safety of CDK2/4/6 inhibitor with endocrine therapy in breast cancer patients, highlighting treatment effects and safety outcomes.

Cite This Study

Yap et al. (2025) studied this question.

synapsesocial.com/papers/689a02bce6551bb0af8cc633 https://doi.org/10.1158/1078-0432.29568356

View Full Paper

Ask AI

Bookmark

Implication

Phase I/IIa trial assessed safety of CDK2/4/6 inhibitor with endocrine therapy in breast cancer patients, highlighting treatment effects and safety outcomes.

Table 2 from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer

Key Points

Discussion

Implication

Cite This Study

Table 2 from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider